Skip to content
Peptigraph home
Injections

Peptide injections: what the FDA labels say about sites, rotation, pens and disposal

Every injectable peptide drug on the market ships with written administration instructions. This page collects what those labels say about injection sites, rotating them, pens versus vials, the U-100 scale and disposing of used pens and needles. It covers approved drugs only. It does not give steps for research peptides, which have no label to quote.

Medical review pendingUpdated 5 min read
Sites named in labels
Abdomen, thigh, upper arm
Varies by drug (Ozempic, Mounjaro, Zepbound)
Rotation
Stated in each label
Quoted drug by drug below
U-100
100 units/mL
As printed on the insulin glargine label
Used needles
FDA-cleared sharps container
Medication Guide wording

Injection sites named in the labels

The labels do not share one list of sites, so it is worth reading each drug's own wording. Ozempic is injected subcutaneously in the abdomen, thigh or upper arm. Mounjaro and Zepbound are injected subcutaneously in the abdomen or thigh, or by another person in the back of the upper arm. Genotropin may be given in the thigh, buttocks or abdomen. Basaglar goes into the abdominal area, thigh or deltoid. Egrifta SV is injected into the abdomen, and Vyleesi into the abdomen or thigh only.

Subcutaneous sites as worded in each label
DrugSites in the labelFrequency in the label
OzempicAbdomen, thigh or upper armOnce weekly
Mounjaro, ZepboundAbdomen, thigh, or back of the upper arm by another personOnce weekly
GenotropinThigh, buttocks or abdomenDaily rotation of site
Egrifta SVAbdomenOnce daily
VyleesiAbdomen or thigh onlyAs needed, at least 45 minutes before sexual activity
BasaglarAbdominal area, thigh or deltoidSee label

The Vyleesi label adds that the site of subcutaneous administration, abdomen or thigh, had no significant effect on the systemic exposure to bremelanotide. That is a statement about one drug, not a rule for others.

Rotating sites

Rotation is written into the labels above, except Vyleesi, whose label has no rotation wording. Ozempic says to use a different injection site each week when injecting in the same body region. Mounjaro and Zepbound say to rotate injection sites with each dose. Genotropin says the site of subcutaneous injections should be rotated daily to help prevent lipoatrophy. Egrifta SV says to rotate injection sites in the abdomen. Basaglar says to rotate within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis.

Where the labels give a reason, it is skin and fat changes or reactions at the injection site: lipoatrophy for Genotropin, lipodystrophy and localized cutaneous amyloidosis for Basaglar, and injection site reactions for Egrifta SV. The Ozempic wording quoted above gives no reason. None of the labels gives a rotation chart.

Pens versus vials

Mounjaro and Zepbound are sold as single-dose pens, single-dose vials, multi-dose vials and single-patient-use KwikPens, and the label tells prescribers to inform patients which presentation they will receive and to ensure training for that specific presentation. For the vials, it instructs patients to use a syringe appropriate for dose administration, for example a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose, and always a new syringe and needle for each injection.

Ozempic pens are fixed-dose devices. The 2 mg/3 mL pen delivers doses in 0.25 mg or 0.5 mg increments only, the 4 mg/3 mL pen in 1 mg increments only, and the 8 mg/3 mL pen delivers 4 doses of 2 mg only. A pen's total milligrams is the contents of the pen, not a dose. Genotropin cartridges are color-coded to a specific Genotropin Pen, and the 5 mg and 12 mg strengths are reconstituted in a reusable device.

Egrifta SV is one labelled example of a peptide mixed by the user: the label says to reconstitute one vial of lyophilized powder with 0.5 mL of the diluent provided, Sterile Water for Injection, to inject 0.35 mL immediately, and to throw away any unused solution and diluent. For reconstitution maths in general see how to reconstitute peptides.

What U-100 means on the label and on the syringe

The insulin glargine label describes its injection as 100 units/mL (U-100). U-100 therefore pairs with the syringe scale in which 100 units is 1 mL. An insulin unit is a measure of insulin; for a peptide in a vial, the scale is only a volume. The step-by-step reading of a barrel is in how to read an insulin syringe.

Units on a syringe are not milligrams The Mounjaro and Zepbound labels describe vial doses as volumes (a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose, for example), not as syringe units. Converting a labelled dose in mg to a draw volume needs the vial's concentration, which the vial's own label gives.

Disposal and not sharing

The Mounjaro and Zepbound Medication Guides say to put the used pen in an FDA-cleared sharps disposal container right away after use. If there is none, they allow a household container that is made of heavy-duty plastic, closes with a tight-fitting puncture-resistant lid without sharps coming out, stays upright and stable during use, is leak-resistant and is properly labeled to warn of hazardous waste inside. When it is almost full they refer to community guidelines. The Basaglar guide gives the same direction for used needles.

Sharing is addressed directly. The Ozempic Medication Guide says not to share the pen with other people, even if the needle has been changed, and not to reuse or share needles. The Mounjaro and Zepbound Medication Guides say the same about their KwikPens and needles, and the Basaglar label says its prefilled pen must never be shared between patients, even if the needle is changed.

The bacteriostatic water label, for the diluent that some products use, says the benzyl alcohol it contains makes it unsuitable for neonates and for epidural or spinal anesthesia. See bacteriostatic water.

Common questions

Where do you inject a peptide?

It depends on the drug. The labels name the abdomen, thigh and upper arm for Ozempic, abdomen, thigh or upper arm by another person for Mounjaro and Zepbound, and abdomen only for Egrifta SV. There is no label for most research peptides, so there is nothing to quote for them.

Do you have to rotate injection sites?

Every label cited here except Vyleesi tells prescribers or patients to rotate sites. Where a reason is given, it is lipoatrophy, lipodystrophy, localized cutaneous amyloidosis or injection site reactions.

Are pens or vials better?

The labels do not rank them. They describe each presentation separately and ask that training match the one the patient receives. Vials need a syringe suitable for the dose volume, and pens deliver fixed doses.

How are used pens and needles thrown away?

The Medication Guides say to use an FDA-cleared sharps disposal container right away after use, or a household container that meets the criteria listed in the guide.

Keep going

Tirzepatide · FDA approved (Mounjaro, Zepbound)Semaglutide · FDA approved (Ozempic, Wegovy, Rybelsus)Tesamorelin · FDA approved (Egrifta)

Sources

  1. 1ZEPBOUND (tirzepatide) injection, prescribing information and Medication Guide (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  2. 2MOUNJARO (tirzepatide) injection, prescribing information and Medication Guide (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3OZEMPIC (semaglutide) injection, prescribing information and Medication Guide (DailyMed)U.S. Food and Drug Administration / DailyMed (Novo Nordisk label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  4. 4EGRIFTA SV (tesamorelin) for injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Theratechnologies label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  5. 5VYLEESI (bremelanotide) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  6. 6GENOTROPIN (somatropin) for injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Pfizer label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  7. 7BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  8. 8Bacteriostatic Water for Injection, USP, label (DailyMed)U.S. Food and Drug Administration / DailyMed (Hospira label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.